GRHPR - morinlab/LLMPP GitHub Wiki



GRHPR is one of a number of genes affected by aberrant somatic hypermutation in B-cell lymphomas, which complicates the interpretation of mutations at this locus. The mutation pattern in DLBCL implies the preferential accumulation of inactivating mutations. Coding and non-coding mutations in GRHPR are a feature of the MCD genetic subgroup of DLBCL.1 Further research is needed to elucidate the specific role of GRHPR mutations in DLBCL.


%%{init: { 'logLevel': 'debug', 'theme': 'dark' } }%%
    title Publication timing
      2018-10-01 : Arthur : DLBCL

Relevance tier by entity

Entity Tier Description
DLBCL 1-a aSHM target and high-confidence DLBCL gene

Mutation incidence in large patient cohorts (GAMBL reanalysis)

Entity source frequency (%)
DLBCL GAMBL genomes 2.68
DLBCL Schmitz cohort 4.47
DLBCL Reddy cohort 3.60
DLBCL Chapuy cohort 4.70

Mutation pattern and selective pressure estimates

Entity aSHM Significant selection dN/dS (missense) dN/dS (nonsense)
BL Yes No 1.819 0.000
DLBCL Yes Yes 10.245 60.346
FL Yes No 0.000 0.000

aSHM regions

chr_name hg19_start hg19_end region regulatory_comment
chr9 37423010 37425279 TSS active_promoter

View coding variants in ProteinPaint hg19 or hg38

View all variants in GenomePaint hg19 or hg38

GRHPR Expression


  1. Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, Wang JQ, Schmitz R, Morin RD, Tang J, Jiang A, Bagaev A, Plotnikova O, Kotlov N, Johnson CA, Wilson WH, Scott DW, Staudt LM. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell. 2020 Apr 13;37(4):551-568.e14. doi: 10.1016/j.ccell.2020.03.015. PMID: 32289277; PMCID: PMC8459709.
⚠️ ** Fallback** ⚠️